BridgeBio LLC
421 Kipling Street
Palo Alto
California
94301
United States
Tel: 650-391-9740
Website: http://bridgebio.com/
Email: info@bridgebio.com
169 articles about BridgeBio LLC
-
BridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases
6/18/2020
Partnership to Leverage University of Florida’s Research in Gene Therapy and BridgeBio’s Translational Expertise in Rare and Genetic Disease
-
BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
6/11/2020
BridgeBio Pharma, Inc. affiliate ML Bio Solutions announced that the first subject has been dosed in the Phase 1 clinical trial of BBP-418, an orally-administered small molecule therapy being evaluated for the treatment of limb girdle muscular dystrophy type 2i.
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 05, 2020
6/5/2020
BridgeBio Pharma, Inc. announced that on June 1, 2020, the compensation committee of BridgeBio’s board of directors granted nine employees options to purchase an aggregate of 55,517 shares of the Company’s common stock with a per share exercise price of $28.88 and restricted stock units for an aggregate of 19,532 shares of the Company’s common stock, including 607 performance-related restricted stock units.
-
BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program
5/29/2020
BridgeBio Pharma, Inc. affiliate QED Therapeutics announced that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, QED’s oral FGFR1-3 inhibitor, in both urothelial carcinoma and cholangiocarcinoma.
-
BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in AchondroplasiaData Accepted to ENDO 2020
5/11/2020
BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that in vitro and in vivo data from two studies support QED’s plans to evaluate a low dose of infigratinib as a treatment option for children with achondroplasia, the most common cause of disproportionate short stature. Data were accepted for presentation at the Endocrine Society's Annual Meeting (“ENDO 2020”), which was cancelled due to COVID-19, and the studies
-
BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference in May 14, 2020
5/6/2020
BridgeBio Pharma, Inc. announced that it will present at the Bank of America Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 11 AM.
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 05, 2020
5/5/2020
BridgeBio Pharma, Inc. announced that on May 1, 2020, the compensation committee of BridgeBio’s board of directors granted five employees options to purchase an aggregate of 39,600 shares of the Company’s common stock with a per share exercise price of $28.97 and restricted stock units for an aggregate of 18,230 shares of the Company’s common stock.
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 03, 2020
4/3/2020
BridgeBio Pharma, Inc. announced that on March 31, 2020, the compensation committee of BridgeBio’s board of directors granted six employees options to purchase an aggregate of 52,916 shares of the Company’s common stock with a per share exercise price of $25.08 and restricted stock units for an aggregate of 22,993 shares of the Company’s common stock.
-
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations
3/12/2020
PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations Ohio State University-Led Trial to Study Infigratinib for Treatment of Patients with Advanced or Metastatic Solid Tumors with FGFR Genetic Alterations
-
Bridge Biotherapeutics Enters AI-based Research Collaboration with Atomwise to Expand Pellino Inhibitor Pipeline
3/9/2020
Atomwise , the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics (KOSDAQ: 288330), a clinical stage biotech company, announced today a research collaboration to launc
-
BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes
3/5/2020
BridgeBio Pharma, Inc. announced the pricing of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress
3/2/2020
BridgeBio Pharma, Inc. (NASDAQ: BBIO), today is reporting its fourth quarter and full year 2019 financial results and recent progress across its portfolio
-
BioSpace Movers & Shakers, Feb. 28
2/28/2020
Biopharma and life sciences strengthen their executive leadership teams and boards with this week's Movers & Shakers. -
BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences
2/22/2020
BridgeBio Pharma, Inc., together with affiliate company Eidos Therapeutics announced that they are presenting at two upcoming investor conferences
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Feb. 05, 2020
2/5/2020
BridgeBio Pharma, Inc. announced that on February 3, 2020, the compensation committee of BridgeBio’s board of directors granted nine new employees options to purchase an aggregate of 96,361 shares of the Company’s common stock with a per share exercise price of $34.81 and restricted stock units for an aggregate of 23,647 shares of the Company’s common stock.
-
With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area.
-
Clinical Catch-Up: January 6-10, 2020
1/13/2020
The first full business week of the new year began with plenty of clinical trial news. Here’s a look. -
BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source
1/13/2020
New assets span multiple modalities and target an endocrine disorder, inherited eye disease, genetically driven deafness and autism spectrum disorder
-
BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma
1/6/2020
The PROOF trial, a Phase 3 trial of infigratinib in first-line cholangiocarcinoma, is currently enrolling